![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 19, 2023
Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
June 30, 2023
Reflections on the spring conference season, including highlights from the recent Group Meeting; updates on the ComboMATCH precision medicine initiative
June 30, 2023
At a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
April 19, 2023
Summaries of recently published ECOG-ACRIN research results
December 20, 2022
Reflections on NCI-MATCH and its successor trials; research results in leukemia and breast cancer; and grant renewal preparations
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
August 16, 2022
President Biden to appoint Dr. Monica Bertagnolli as NCI Director; NCI-MATCH trial data leads to FDA drug approval
August 16, 2022
Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
April 15, 2022
The ground-breaking NCI-MATCH precision medicine cancer trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. Lead investigators Nilo Azad, MD, and April Salama, MD, discuss Arms Z1M and H.